澳大利亚专利AU2010215203A1 Medical devices with an activated coating

专利PDF首页>>澳大利亚专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Implantable medical devices include a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity.
公开号:AU2010215203A1
申请号:U2010215203
申请日:2010-02-22
公开日:2011-10-13
发明作者:Ahmad Robert Hadba；Sebastien Ladet
申请人:Sofradim Production SAS；Tyco Healthcare Group LP；
IPC主号:C08J7-04

专利说明:
WO 2010/095056 PCT/IB2010/000665 MEDICAL DEVICES WITH AN ACTIVATED COATING BACKGROUND Technical Field The present disclosure relates to implantable devices having coating that imparts an activated surface to the device. Background of Related Art Methods for making monofilaments that are suitable to fabricate surgical articles, such as sutures, generally include the steps of extruding at least one bioabsorbable or nonbioabsorbable polymer to provide filaments, drawing or stretching the solidified filaments to achieve molecular orientation, and annealing the drawn filaments to relieve internal stresses. Various spinning methods may be employed, such as melt spinning, gel spinning, wet or dry spinning, and reaction spinning. Melt spinning uses heat and potentially shear to melt the fiber-forming polymer to a viscosity suitable for extrusion through the die or spinneret. After exiting the die, the fiber solidifies by cooling in air or a suitable chilled fluid bath. In solvent spinning, the fiber-forming polymer is dissolved in a suitable organic solvents or solvent mixture to result in a fluid with suitable viscosity for extrusion through a spinneret. The difference between wet and dry spinning is the means by which the fiber solidifies. In dry spinning, the fiber solidifies as the solvent evaporates under a stream of air or inert gas. In wet spinning, the fiber forms by precipitating from solution as a result of dilution in a non-solvent bath or chemical reaction with a crosslinker in the solvent bath. Gel spinning refers to a process similar to solvent spinning except that the polymer is not fully dissolved in the solvent- a high polymer content is used in the process. The chains of the partially solvated polymer are aligned by the shear during WO 2010/095056 PCT/IB2010/000665 the extrusion process. The filaments are further drawn as they are passed through a gas drying then a wet precipitating bath. The resulting fibers have an unusually high degree of allignmnet and high tensile strength relative to conventional melt or solvent spinning techniques. Reaction spinning involves the formation of filaments from reactive polymers or prepolymers and monomers that are further polymerized and cross-linked during the extrusion process or after the fiber or filament is formed. Click chemistry refers to a collection of reactions capable of forming a highly reliable molecular connection in solution or bulk state. Click chemistry reactions may be highly selective, high yield reactions which should not interfere with one another as well as other reactions. It would be desirable to make filaments useful in making surgical devices by extruding a mixture containing first and second precursors functionalized for crosslinking by click chemistry and aided by the process controls of the spinning process, such as temperature, pressure, and time. SUMMARY A first aspect of the invention is a method of producing a medical device comprising: coating a substrate with a polymer possessing a core and at least one functional group known to have click reactivity, whereby a medical device with an activated surface is produced. In the present application, unless otherwise specified, the expressions 'functional group", "functional group known to have click reactivity" and "reactive member" are used interchangeably to designate a functional group known to have click reactivity. 2 WO 2010/095056 PCT/IB2010/000665 In the present application, unless otherwise specified, the expression "functionalized polymer" means the polymer possessing the functional group as defined herein. Another aspect of the invention is a medical device comprising a substrate having a coating, the coating comprising a polymer possessing a functional group having click reactivity. In embodiments, the substrate is a biocompatible polymeric substrate. The biocompatible polymeric substrate may include fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon and combinations thereof. The core may be prepared from synthetic materials selected from poly(lactic acid), poly(glycolic acid), poly(lactide), poly(glycolide), poly(trimethylene carbonate), poly(p dioxanone), polyhydroxybutyrate, polyphosphazine, polyesters, poly(ethylene terephthalate), ultra-high molecular weight polyethylene, poly(ethylene glycol)s, poly(ethylene oxide)s, polyacrylamides, poly(hydroxyethyl methylacrylate), poly(vinylpyrrolidone), poly(vinyl alcohol)s, poly(acrylic acid), polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), poly(alkylene oxalate)s, poly (saccharides), polyamides, poly (iminocarbonates), polyoxaesters, polyorthoesters, polyphosphazenes, biopolymers, polymer drugs and copolymers, block copolymers, homopolymers, blends and combinations thereof. In embodiments, the core may be prepared from natural polymers selected from collagen, cellulose, poly (amino acids), polysaccharides, chitosan and chitosan derivatives (e.g., chitosan acetate/formate polymers), hyaluronic acid, gut, copolymers and combinations thereof. In embodiments, the functional group known to have click reactivity is selected from the group consisting in an amine, sulfate, thiols, hydroxyl, azides, alkynes, alkenes, carboxyl groups, 3 WO 2010/095056 PCT/IB2010/000665 aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as -CO 2
N(COCH
2
)
2 , CO 2
N(COCH
2
)
2 , -CO 2 H, -CHO, -CHOCH 2 , -N=C=O, -SO 2
CH=CH
2 , -N(COCH) 2 , -S-S
(C
5
H
4 N), and/or groups of the following structures wherein X is halogen and R is hydrogen or C1 to C 4 alkyl: / x 0N N E R R R R R R R For example, the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes. In particular, the functional group known to have click reactivity may be a thiol. Alternatively, the functional group known to have click reactivity may be an azide. Alternatively, the functional group known to have click reactivity may be an alkyne. Alternatively, the functional group known to have click reactivity may be an alkene. Implantable medical devices with an activated surface in accordance with this disclosure are fabricated from a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity. The coating thus provides the implantable medical device with a plurality of functional groups known to have click reactivity at the surface thereof. 4 WO 2010/095056 PCT/IB2010/000665 DETAILED DESCRIPTION OF EMBODIMENTS Implantable medical devices in accordance with the present disclosure are prepared from a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity. The coating thus provides the implantable medical device with a plurality of functional groups known to have click reactivity at the surface thereof. The Polymeric Substrate The substrate of the medical devices described herein may be made from any biocompatible polymer. The biocompatible polymer may be a homopolymer or a copolymer, including random copolymer, block copolymer, or graft copolymer. The biocompatible polymer may be a linear polymer, a branched polymer, or a dendrimer. The biocompatible polymer may be bioabsorbable or non-absorbable and may be of natural or synthetic origin. Examples of suitable biodegradable polymers from which the substrate of the medical devices described herein may be made include, but are not limited to polymers such as those made from alpha-hydroxy acids (e.g. lactic acid, glycolic acid, and the like), lactide, glycolide, 6 caprolactone, 3-valerolactone, carbonates (e.g., trimethylene carbonate, tetramethylene carbonate, and the like), dioxanones (e.g., 1,4-dioxanone), 3-valerolactone, 1,dioxepanones (e.g., 1,4-dioxepan-2-one and 1,5-dioxepan-2-one), ethylene glycol, ethylene oxide, esteramides, hydroxy alkanoates (e.g. -y-hydroxyvalerate, fl-hydroxypropionate, 3-hydroxybuterate, and the like), poly (ortho esters), tyrosine carbonates, polyimide carbonates, polyimino carbonates such as poly (bisphenol A-iminocarbonate) and poly (hydroquinone-iminocarbonate), polyurethanes, polyanhydrides, polymer drugs (e.g., polydiflunisol, polyaspirin, and protein therapeutics) and copolymers and combinations thereof. Suitable natural biodegradable polymers include 5 WO 2010/095056 PCT/IB2010/000665 collagen, cellulose, poly (amino acids), polysaccharides, hyaluronic acid, gut, copolymers and combinations thereof. Examples of suitable non-degradable polymers from which the substrate of the medical devices described herein may be made include, but are not limited to fluorinated polymers (e.g.fluoroethylenes, propylenes, fluoroPEGs), polyolefins such as polyethylene, polyesters such as poly ethylene terepththalate (PET), nylons, polyamides, polyurethanes, silicones, ultra high molecular weight polyethylene (UHMWPE), polybutesters, polyaryletherketone, copolymers and combinations thereof. The biocompatible polymeric substrate may be fabricated into any desired physical form. The polymeric substrate may be fabricated for example, by spinning, casting, molding or any other fabrication technique known to those skilled in the art. The polymeric substrate may be made into any shape, such as, for example, a fiber, sheet, rod, staple, clip, needle, tube, foam, or any other configuration suitable for a medical device. Where the polymeric substrate is in the form of a fiber, the fiber may be formed into a textile using any known technique including, but not limited to, knitting, weaving, tatting and the like. It is further contemplated that the polymeric substrate may be a non-woven fibrous structure. The present biocompatible polymeric substrate can be part of any medical device of being implanted at a target location. Some non-limiting examples include fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon, and the like. The implantable device can be intended for permanent or temporary implantation. 6 WO 2010/095056 PCT/IB2010/000665 The Coating The coating applied to the substrate in accordance with the present disclosure includes a polymer having at least one functional group known to have click reactivity. The polymer used in the coating possesses a core that is functionalized with one or more reactive members. The core of the polymer may be any suitable biocompatible polymer. The core may be a homopolymer or a copolymer, including random copolymer, block copolymer, or graft copolymer. The core may be a linear polymer, a branched polymer, or a dendrimer. The core of may be a natural material or a synthetic material and may be bioabsorbable or non bioabsorbable. It should of course be understood that any combination of natural, synthetic, bioabsorbable and non-bioabsorbable materials may be used to form the implantable medical device. Some non-limiting examples of synthetic materials from which the core may be prepared include, but are not limited to poly(lactic acid), poly(glycolic acid), poly(lactide), poly(glycolide), poly(trimethylene carbonate), poly(p-dioxanone), polyhydroxybutyrate, polyphosphazine, polyesters, poly(ethylene terephthalate), ultra-high molecular weight polyethylene, poly(ethylene glycol)s, poly(ethylene oxide)s, polyacrylamides, poly(hydroxyethyl methylacrylate), poly(vinylpyrrolidone), poly(vinyl alcohol)s, poly(acrylic acid), polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), poly(alkylene oxalate)s, poly (saccharides), polyamides, poly (iminocarbonates), polyoxaesters, polyorthoesters, polyphosphazenes, biopolymers, polymer drugs and copolymers, block copolymers, homopolymers, blends and combinations thereof. Suitable natural polymers from which the core may be prepared include collagen, cellulose, poly (amino acids), 7 WO 2010/095056 PCT/IB2010/000665 polysaccharides, chitosan and chitosan derivatives (e.g., chitosan acetate/formate polymers), hyaluronic acid, gut, copolymers and combinations thereof. In preparing a coating in accordance with the present disclosure, the polymer may be commercially available pre-functionalized cores or may be synthesized. It is contemplated that a plurality of different reactive members may be present and that they may be terminally located, or alternatively located along the length of the polymer chain. In embodiments, the polymer has from about 2 to about 50 reactive members. Examples of the types of reactions that are known to have click reactivity include cycloaddition reactions. Cycloaddition reactions can be used to form the medical devices, for example fibers, of the present disclosure. These reactions represent highly specific reactant pairs that have a chemoselective nature, meaning that they mainly react with each other and not with other functional members (i.e. different from functional groups and reactive members herein). One example of a cycloaddition reaction is the Huisgen 1,3-dipolar cycloaddition of a dipolarophile with a 1,3 dipolar component that produce five membered (hetero)cycles. Examples of dipolarophiles are alkenes, alkynes, and molecules that possess related heteroatom functional groups, such as carbonyls and nitriles. Specifically, another example is the 2+3 cycloaddition of alkyl azides and acetylenes. Other cycloaddition reactions include Diels-Alder reactions of a conjugated diene and a dienophile (such as an alkyne or alkene). Other examples of the types of reactions that are known to have click reactivity include a hydrosilation reaction of H-Si and simple non-activated vinyl compounds, urethane formation from alcohols and isocyanates, Menshutkin reactions of tertiary amines with alkyl iodides or alkyl trifluoromethanesulfonates, Michael additions, e.g., the very efficient maleimide-thiol reaction, atom transfer radical addition reactions between -S02C1 and an olefin (R',R 2
-C=C
8 WO 2010/095056 PCT/IB2010/000665
R
3
,R
4 ), metathesis, Staudinger reaction of phosphines with alkyl azides, oxidative coupling of thiols, many of the procedures already used in dendrimer synthesis, especially in a convergent approach, which require high selectivity and rates, nucleophilic substitution, especially of small strained rings like epoxy and aziridine compounds, carbonyl chemistry like formation of ureas, and addition reactions to carbon-carbon double bonds like dihydroxylation. Therefore, attached functionality may be chosen from acetylene bond, an azido-group, a nitrile group, acetylenic, amino group, phosphino group. The click chemistry reaction may results in the addition of a functional group selected from amino, primary amino, hydroxyl, sulfonate, benzotriazole, bromide, chloride, chloroformate, trimethylsilane, phosphonium bromide or bio-responsive functional group including polypeptides, proteins and nucleic acids, to the polymer. Thus, suitable reactive members that may be applied to the core include, for example, an amine, sulfate, thiosl, hydroxyl, azides, alkynes, alkenes, carboxyl groups, aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as -CO 2
N(COCH
2
)
2 , -CO 2
N(COCH
2
)
2 , -CO 2 H, -CHO, -CHOCH 2 , -N=C=O, -SO 2
CH=CH
2 , -N(COCH) 2 , -S-S-(C 5
H
4 N), and/or groups of the following structures wherein X is halogen and R is hydrogen or C 1 to C 4 alkyl: x 0 N N R R R R R R R In embodiments, the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes. 9 WO 2010/095056 PCT/IB2010/000665 The core of the polymer can be provided with click reactive members using any variety of suitable chemical processes. For example, the monomers from which the core is made can be functionalized so that the reactive members appear along the length of the core. In such embodiments, monomers can be initially functionalized with a group such as a halogen to provide a reactive site at which the desired first click reactive member can be attached after polymerization. Thus, for example, a cyclic lactone (e.g., glycolide, lactide, caprolactone, etc.) can be halogenated and then polymerized using known techniques for ring opening polymerization. Once polymerized, the halogenated sites along the resulting polyester chain can be functionalized with a click reactive member, for example, by converting pendant chlorides on the core into azides by reaction with sodium azide. See, R. Riva et al., Polymer 49 pages 2023-2028 (2008) for a description of such reaction schemes. Other methods for functionalizing lactones are described in Jr6me et al., Advanced Drug Delivery Reviews, 60, pages 1056-1076 (2008) and Shi et al., Biomaterials, 29 pages 1118-1126 (2008). The entire disclosure of each of these three articles is incorporated herein by this reference. Alternatively, the polymer or copolymer backbone may be halogenated using methods similar to those described by Nottelet et al., Biomaterials, 27, pages 4948-4954 (2006). Once halogenated, the backbone can be functionalized with a click reactive functionality by reacting it with a hydroxyacid under condition described by Shi et al. Biomaterials, 29, pages 1118-1126 (2008) followed by reaction with sodium azide. The halogen may also be converted directly to the alkyne by reacting it with an alcoholic alkyne such as propargyl alcohol. 10 WO 2010/095056 PCT/IB2010/000665 Those skilled in the art reading this disclosure will readily envision chemical reactions for activating other core materials to render them suitable for use in coatings in the presently described methods. Applying the Coating to the Substrate A composition containing the functionalized polymer described herein can be applied to the substrate employing techniques known to one skilled in the art, e.g., by dipping, wiping, spraying, total immersion, co-extrusion, etc. For example, the coating may be applied by passing the substrate through a solution of the polymer, passing the substrate past a brush or other coating solution applicator, or passing the substrate past one or more spray nozzles dispensing the suture coating solution. The substrate wetted with the coating composition can be passed through or held in a drying oven for a time and at a temperature sufficient to vaporize and drive off the solvent. The coating composition may take the form of any solution, suspension, semi-solid, or solid material capable of allowing the functionalized polymer to be applied as a coating to the substrate. The polymer may be in granular, pellet, or powder form, or alternatively, may be in a dilute solution. Suitable solvents which may be utilized to form a dilute solution include any biocompatible solvent within the purview of those skilled in the art which will not interfere with the reaction of the reactive members of the first and second precursors. Suitable solvents which may be utilized include, for example, polar solvents such as water, ethanol, triethylene glycol, dimethyl sulfoxide, glymes (such as diglyme, triglyme, tetraglyme, and the like), polyethylene glycols, methoxy-polyethylene glycols, dimethylformamide, dimethylacetamide, gamma butyrolactone, n-methylpyrollidone, ketones such as methyl ethyl ketone, cyclohexanone, diethylene glycol momethyl ether acetate, diethylene glycol monobutyl ether acetate, diethylene 11 WO 2010/095056 PCT/IB2010/000665 glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoisobutyl either, diisobutyl ketone, diacetone alcohol, ethyl amyl ketone, ethyl lactate, and the like. In other embodiments, solvents such as tetrahydrofuran, ethyl acetate, isopropyl acetate, butyl acetate, isopropanol, butanol, acetone, and the like, may be utilized. In embodiments, combinations of any of the foregoing solvents may be utilized to form a dilute solution. The amount of solvent used will depend on a number of factors, including the particular polymer(s) to be employed in the coating composition. In each case, the resulting coated substrate possesses click reactive functional groups at the surface thereof. The present medical devices may further be use for delivery of a bioactive agent. Thus, in some embodiments, at least one bioactive agent may be combined with polymer to form the coating composition. The agents may be freely admixed with the functionalized polymer or may be tethered to the polymers through any variety of chemical bonds. In these embodiments, the present devices can also serve as a vehicle for delivery of the bioactive agent. The term "bioactive agent," as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, an anti-adhesive compound, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes. It is envisioned that the bioactive agent may be applied to the present devices in any suitable form of matter, e.g., films, powders, liquids, gels and the like. 12 WO 2010/095056 PCT/IB2010/000665 Examples of classes of bioactive agents which optionally may be utilized in accordance with the coatings of the present disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, platelet activating drugs, clotting factors and enzymes. It is also intended that combinations of bioactive agents may be used. Anti-adhesive agents can be used to prevent adhesions from forming between the implantable medical device and the surrounding tissues opposite the target tissue. In addition, anti-adhesive agents may be used to prevent adhesions from forming between the coated implantable medical device and the packaging material. Some examples of these agents include, but are not limited to hydrophilic polymers such as poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols, and combinations thereof. Suitable antimicrobial agents which optionally may be included as a bioactive agent in the coating of the present disclosure include triclosan, also known as 2,4,4'-trichloro-2' hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins 13 WO 2010/095056 PCT/IB2010/000665 such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the present disclosure. Other bioactive agents which may be included as a bioactive agent in the coating composition applied in accordance with the present disclosure include: local anesthetics; non steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; chemotherapeutics, estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents. Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, 14 WO 2010/095056 PCT/IB2010/000665 IL-4, IL-6), interferons (fl-IFN, (ci-IFN and yIFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, fibrin, thrombin, fibrinogen, synthetic thrombin, synthetic fibrin, synthetic fibrinogen, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); bone morphogenic proteins, TGF-B, protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA, RNA, RNAi; oligonucleotides; polynucleotides; and ribozymes. Medical devices having an activated surface in accordance with the present disclosure can be used for a variety of purposes. For example, in embodiments they may be used for drug delivery. In such embodiments, the drug to be delivered is functionalized with one or more reactive members that are complementary to the reactive members in the coating at the surface of the device. By "complementary" it is meant that the reactive members on the drug to be delivered are able to interact with the reactive members in the coating at the surface of the device to covalently bond the drug to be delivered to the surface of the device. In other embodiments, the medical device having an activated surface in accordance with the present disclosure can be attached to biological tissue by functionalizing tissue with one or more reactive member that are complementary to the reactive members in the coating at the surface of the device. Biological tissue can be provided with reactive member that are complementary to the reactive members in the coating at the surface of the device by conjugation of such groups to various components of tissue such as proteins, lipids, oligosaccharides, oligonucleotides, glycans, including glycosaminoglycans. In embodiments, the complementary 15 WO 2010/095056 PCT/IB2010/000665 groups are attached directly to components of the tissue. In other embodiments, the complementary groups are attached to components of the tissue via a linker. In either case, situating the complementary groups on the tissue can be accomplished by suspending the reactive member in a solution or suspension and applying the solution or suspension to the tissue such that the reactive member binds to a target. The solution or suspension may be poured, sprayed or painted onto the tissue, whereupon the reactive members are incorporated into the tissue. Those skilled in the art reading this disclosure will readily envision other uses for the activated medical devices described herein. While several embodiments of the disclosure have been described, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto. 16

权利要求:
Claims (16)
[1] 1. A method of producing a medical device comprising: coating a substrate with a polymer possessing a core and at least one functional group known to have click reactivity, whereby a medical device with an activated surface is produced.
[2] 2. The method of claim 1, wherein the substrate is a biocompatible polymeric substrate.
[3] 3. The method of claim 2, wherein the biocompatible polymeric substrate includes fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon and combinations thereof.
[4] 4. The method of any of claims 1 to 3, wherein the core is prepared from synthetic materials selected from poly(lactic acid), poly(glycolic acid), poly(lactide), poly(glycolide), poly(trimethylene carbonate), poly(p-dioxanone), polyhydroxybutyrate, polyphosphazine, polyesters, poly(ethylene terephthalate), ultra-high molecular weight polyethylene, poly(ethylene glycol)s, poly(ethylene oxide)s, polyacrylamides, poly(hydroxyethyl methylacrylate), poly(vinylpyrrolidone), poly(vinyl alcohol)s, poly(acrylic acid), polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), poly(alkylene oxalate)s, poly (saccharides), polyamides, poly (iminocarbonates), polyoxaesters, polyorthoesters, polyphosphazenes, biopolymers, polymer drugs and copolymers, block copolymers, homopolymers, blends and combinations thereof. 17 WO 2010/095056 PCT/IB2010/000665
[5] 5. The method of any one of claims 1 to 3, wherein the core is prepared from natural polymers selected from collagen, cellulose, poly (amino acids), polysaccharides, chitosan and chitosan derivatives (e.g., chitosan acetate/formate polymers), hyaluronic acid, gut, copolymers and combinations thereof.
[6] 6. The method according to any one of claims 1 to 5, wherein the functional group known to have click reactivity is selected from the group consisting in an amine, sulfate, thiols, hydroxyl, azides, alkynes, alkenes, carboxyl groups, aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as -CO 2 N(COCH 2 ) 2 , -CO 2 N(COCH 2 ) 2 , -CO 2 H, -CHO, -CHOCH 2 , -N=C=0, -SO 2 CH=CH 2 , -N(COCH) 2 , -S-S-(C 5 H4N), and/or groups of the following structures wherein X is halogen and R is hydrogen or Ci to C 4 alkyl: x R R R R R R R
[7] 7. The method according to claim 6, wherein the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes.
[8] 8. A medical device comprising a substrate having a coating, the coating comprising a polymer possessing a functional group having click reactivity. 18 WO 2010/095056 PCT/IB2010/000665
[9] 9. The medical device of claim 8, wherein the substrate is a biocompatible polymeric substrate.
[10] 10. The medical device of claim 9, wherein the biocompatible polymeric substrate includes fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon and combinations thereof.
[11] 11. The medical device according to any one of claims 8 to 10, wherein the functional group known to have click reactivity is selected from the group consisting in an amine, sulfate, thiols, hydroxyl, azides, alkynes, alkenes, carboxyl groups, aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as -CO 2 N(COCH 2 ) 2 , -CO 2 N(COCH 2 ) 2 , -CO 2 H, -CHO, -CHOCH 2 , -N=C=O, -SO 2 CH=CH 2 , -N(COCH) 2 , -S-S-(C 5 H 4 N), and/or groups of the following structures wherein X is halogen and R is hydrogen or Ci to C 4 alkyl: X 0N N ( R R R R R R R R
[12] 12. The medical device according to claim 11, wherein the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes.
[13] 13. The medical device according to claim 12, wherein the functional group known to have click reactivity is a thiol. 19 WO 2010/095056 PCT/IB2010/000665
[14] 14. The medical device according to claim 12, wherein the functional group known to have click reactivity is an azide.
[15] 15. The medical device according to claim 12, wherein the functional group known to have click reactivity is an alkyne.
[16] 16. The medical device according to claim 12, wherein the functional group known to have click reactivity is an alkene. 20

类似技术:

公开号 | 公开日 | 专利标题

US9511175B2|2016-12-06|Medical devices with an activated coating

EP2181722B1|2015-01-14|Delayed gelation compositions and methods of use

US9421296B2|2016-08-23|Crosslinked fibers and method of making same by extrusion

AU2010215204B2|2014-12-18|Fibers with an activated surface and method of making same by extrusion

AU2010215194A1|2011-10-13|Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices

US20110015672A1|2011-01-20|Method for Coating a Medical Device

CA2804263A1|2012-01-12|Microwave-powered reactor and method for in situ forming implants

US10196762B2|2019-02-05|Enhanced suture braid strength through click chemistry

AU2011232343B2|2015-05-07|Chemical knots for sutures

ES2402110T3|2013-04-29|Crosslinked fibers and process thereof using transition metal ions

同族专利:

公开号 | 公开日

US20120021037A1|2012-01-26|

US20160175490A1|2016-06-23|

WO2010095056A3|2010-10-28|

CA2753173C|2017-05-30|

CA2753173A1|2010-08-26|

WO2010095056A2|2010-08-26|

US9273191B2|2016-03-01|

AU2010215203B2|2015-07-16|

EP2398850A2|2011-12-28|

US9511175B2|2016-12-06|

EP2398850B1|2018-08-22|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US3767085A|1971-08-02|1973-10-23|J Cannon|Mixing syringe|

AT366916B|1980-04-02|1982-05-25|Immuno Ag|DEVICE FOR APPLICATING A TISSUE ADHESIVE BASED ON HUMAN OR ANIMAL PROTEINS|

US4326532A|1980-10-06|1982-04-27|Minnesota Mining And Manufacturing Company|Antithrombogenic articles|

IT1144925B|1981-10-08|1986-10-29|Anic Spa|CHITOSAN QUARRY FIBERS AND PROCEDURE FOR THEIR OBTAINING|

US4538920A|1983-03-03|1985-09-03|Minnesota Mining And Manufacturing Company|Static mixing device|

US4839345A|1985-03-09|1989-06-13|Nippon Oil And Fats Co., Ltd.|Hydrated adhesive gel and method for preparing the same|

US4857403A|1986-12-16|1989-08-15|E. I. Du Pont De Nemours And Company|High strength fibers from chitin derivatives|

US5021207A|1986-12-16|1991-06-04|E. I. Du Pont De Nemours And Company|High strength fibers from chitin derivatives|

DE3702999C2|1987-02-02|2003-03-06|Siemens Ag|Apparatus for processing UV-curable reaction resin compositions and their use|

US4753536A|1987-03-09|1988-06-28|Spehar Edward R|Dispensing mixer for the storage and mixing of separate materials|

SE500503C2|1990-12-07|1994-07-04|Inst Polymerutveckling Ab|Method and irradiation unit for continuous cross-linking of polyethylene|

US5455308A|1991-08-01|1995-10-03|Dsm N.V.|Endless objects from epoxy resin or unsaturated polyester and thermoplastic polymer|

US5372585A|1992-04-09|1994-12-13|Tiefenbrun; Jonathan|Instrument and associated method for applying biologically effective composition during laparoscopic operation|

US5582955A|1994-06-23|1996-12-10|State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon|Chemical functionalization of surfaces|

AU686613B2|1993-03-23|1998-02-12|Focal, Inc.|Apparatus and method for local application of polymeric material to tissue|

BE1008260A6|1994-04-14|1996-02-27|Dsb Nv|Amphiphile polyurethane charged with medicine which is coated onto vascularstents for the treatment of blood vessel constriction|

US5578662A|1994-07-22|1996-11-26|United States Surgical Corporation|Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom|

US5911942A|1995-11-02|1999-06-15|Tissue Engineering, Inc.|Method for spinning and processing collagen fiber|

US5562946A|1994-11-02|1996-10-08|Tissue Engineering, Inc.|Apparatus and method for spinning and processing collagen fiber|

US5869127A|1995-02-22|1999-02-09|Boston Scientific Corporation|Method of providing a substrate with a bio-active/biocompatible coating|

US6107453A|1995-07-28|2000-08-22|Sanitaria Scaligera S.P.A.|Process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated|

US5804318A|1995-10-26|1998-09-08|Corvita Corporation|Lubricious hydrogel surface modification|

FR2766717B1|1997-08-01|2000-06-09|Cogent Sarl|COMPOSITE PROSTHESIS FOR PREVENTION OF POST-SURGICAL ADHESIONS AND PROCESS FOR OBTAINING SAME|

US6107365A|1997-09-03|2000-08-22|The Regents Of The University Of California|Biomimetic hydrogel materials|

CA2222837A1|1997-11-28|1999-05-28|Brent R. Stranix|Cycloaddition functional polymers from polystyrene|

US6342591B1|1998-09-22|2002-01-29|Biosurface Engineering Technologies, Inc.|Amphipathic coating for modulating cellular adhesion composition and methods|

US8016881B2|2002-07-31|2011-09-13|Icon Interventional Systems, Inc.|Sutures and surgical staples for anastamoses, wound closures, and surgical closures|

US6958212B1|1999-02-01|2005-10-25|Eidgenossische Technische Hochschule Zurich|Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds|

US6312725B1|1999-04-16|2001-11-06|Cohesion Technologies, Inc.|Rapid gelling biocompatible polymer composition|

US6423818B1|1999-07-30|2002-07-23|Takehisa Matsuda|Coumarin endcapped absorbable polymers|

DE60120650T2|2000-03-16|2007-05-31|The Regents Of The University Of California, Oakland|CHEMOSELECTIVE ANNOUNCEMENT BY USING A PHOSPHINE|

US7064151B1|2000-04-07|2006-06-20|E. I. Du Pont De Nemours And Company|Process of microgel synthesis and products produced therefrom|

WO2002013701A1|2000-08-17|2002-02-21|Tyco Healthcare Group Lp|Sutures and coatings made from therapeutic absorbable glass|

US6576000B2|2001-03-06|2003-06-10|Scimed Life Systems, Inc.|Devices and methods for tissue repair|

US6808908B2|2001-05-30|2004-10-26|Porex Technologies Corporation|Functionalized porous substrate for binding chemical and biological moieties|

FR2827799A1|2001-07-27|2003-01-31|Sofradim Production|Coating metal substrates with polysaccharide, e.g. for production of vascular endoprostheses, involves chemical modification, application of a reactive silane as coupling agent and coating with polysaccharide solution|

US7294357B2|2001-09-28|2007-11-13|Tyco Healthcare Group Lp|Plasma coated sutures|

US8501165B2|2001-12-12|2013-08-06|Promethean Surgical Devices Llc|In situ bonds|

US20030162903A1|2001-12-21|2003-08-28|Day James F.|High temperature stable fluorochemical graft polymers as hydrophobic, oleophobic and alcohol-resistant additives to synthetic organic polymers|

AU2003215280A1|2002-02-15|2003-09-09|Northwestern University|Self-assembly of peptide-amphiphile nanofibers under physiological conditions|

AU2003232031A1|2002-05-03|2003-11-17|Gambro, Inc.|Fluid mixing and irradiation device and method of using the device especially for biological fluids|

WO2003101972A1|2002-05-30|2003-12-11|The Scripps Research Institute|Copper-catalysed ligation of azides and acetylenes|

US7591994B2|2002-12-13|2009-09-22|Immunomedics, Inc.|Camptothecin-binding moiety conjugates|

CA2508831C|2002-12-13|2012-05-01|Immunomedics, Inc.|Immunoconjugates with an intracellularly-cleavable linkage|

US8877901B2|2002-12-13|2014-11-04|Immunomedics, Inc.|Camptothecin-binding moiety conjugates|

US20050032081A1|2002-12-13|2005-02-10|Jingyue Ju|Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry|

US7172877B2|2003-01-09|2007-02-06|Massachusetts Institute Of Technology|Methods and compositions for peptide and protein labeling|

US20050233389A1|2003-01-09|2005-10-20|Massachusetts Institute Of Technology|Methods and compositions for peptide and protein labeling|

US7655038B2|2003-02-28|2010-02-02|Biointeractions Ltd.|Polymeric network system for medical devices and methods of use|

US8034619B2|2003-12-19|2011-10-11|University Of Cincinnati|Polyamides for nucleic acid delivery|

US7833978B2|2004-02-20|2010-11-16|Emory University|Thrombomodulin derivatives and conjugates|

EP1730307A4|2004-03-03|2008-11-05|Univ Columbia|Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry|

US7795355B2|2004-03-05|2010-09-14|Carnegie Mellon University|Preparation of functional polymers|

WO2005097223A1|2004-03-26|2005-10-20|Surmodics, Inc.|Composition and method for preparing biocompatible surfaces|

US7985424B2|2004-04-20|2011-07-26|Dendritic Nanotechnologies Inc.|Dendritic polymers with enhanced amplification and interior functionality|

ES2547220T3|2004-04-20|2015-10-02|Dendritic Nanotechnologies, Inc.|Dendritic polymers with enhanced amplification and interior functionality|

GB0411186D0|2004-05-19|2004-06-23|Celltech R&D Ltd|Biological products|

WO2006002399A2|2004-06-24|2006-01-05|Surmodics, Inc.|Biodegradable implantable medical devices, methods and systems|

JP2008505224A|2004-06-30|2008-02-21|ザスクリプスリサーチインスティテュート|Click chemistry route to triazole dendrimers|

US20080138317A1|2004-06-30|2008-06-12|Ramie Fung|Use of biocompatible amphiphilic polymers as an anti-inflammatory agent|

EP1778411A4|2004-07-22|2012-05-09|Scripps Research Inst|Polymeric materials via click chemistry|

US7157538B2|2004-08-13|2007-01-02|Alcon, Inc.|Covalently-bound, hydrophilic coating compositions for surgical implants|

EP1827678B1|2004-08-31|2012-07-18|Total Synthesis Ltd.|Method and apparatus for performing micro-scale chemical reactions|

US7247692B2|2004-09-30|2007-07-24|Johnson & Johnson Vision Care, Inc.|Biomedical devices containing amphiphilic block copolymers|

WO2006044800A2|2004-10-18|2006-04-27|Tyco Healthcare Group, Lp|Structure for applying sprayable wound treatment material|

US7717313B2|2004-10-18|2010-05-18|Tyco Healthcare Group Lp|Surgical apparatus and structure for applying sprayable wound treatment material|

US8357147B2|2005-08-17|2013-01-22|Spinal Restoration, Inc.|Method for repairing intervertebral discs|

WO2006050262A2|2004-11-01|2006-05-11|The Regents Of The University Of California|Compositions and methods for modification of biomolecules|

US20060147963A1|2004-12-30|2006-07-06|Affymetrix, Inc.|Detection of polynucleotides on nucleic acid arrays using azido-modified triphosphate nucleotide analogs|

EP1853967A4|2005-02-03|2009-11-11|Univ North Carolina|Low surface energy polymeric material for use in liquid crystal displays|

CN101500420A|2005-02-25|2009-08-05|加州大学评议会|New polymeric materials and methods|

US7638558B2|2005-04-01|2009-12-29|Intezyne Technologies, Inc.|Polymeric micelles for drug delivery|

US7550143B2|2005-04-06|2009-06-23|Ibc Pharmaceuticals, Inc.|Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses|

AU2006232920B2|2005-04-06|2011-09-29|Ibc Pharmaceuticals, Inc.|Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses|

US7534866B2|2005-10-19|2009-05-19|Ibc Pharmaceuticals, Inc.|Methods and compositions for generating bioactive assemblies of increased complexity and uses|

US7527787B2|2005-10-19|2009-05-05|Ibc Pharmaceuticals, Inc.|Multivalent immunoglobulin-based bioactive assemblies|

WO2007002109A2|2005-06-20|2007-01-04|The Regents Of The University Of California|Multidentate pyrone-derived chelators for medicinal imaging and chelation|

US9290617B2|2005-07-06|2016-03-22|Molly S. Shoichet|Method of biomolecule immobilization on polymers using click-type chemistry|

US20070020620A1|2005-07-14|2007-01-25|Finn M G|Compositions and methods for coupling a plurality of compounds to a scaffold|

US20090306310A1|2005-07-18|2009-12-10|The Scripps Research Institute|Method of using click chemistry to functionalize dendrimers|

US20090182151A1|2005-07-18|2009-07-16|The Scripps Research Institute|Method for making amphiphilic dendrimers|

EP1922364A4|2005-08-09|2010-04-21|Univ North Carolina|Methods and materials for fabricating microfluidic devices|

US8008453B2|2005-08-12|2011-08-30|Amgen Inc.|Modified Fc molecules|

US20070060658A1|2005-08-31|2007-03-15|Diaz David D|Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition|

CA2622955A1|2005-09-15|2007-03-29|University Of Utah Research Foundation|Polymeric compositions and methods of making and using thereof|

WO2007041451A2|2005-09-30|2007-04-12|The Scripps Research Institute|Ruthenium-catalyzed cycloaddition of alkynes and organic azides|

CA2622872A1|2005-09-30|2007-04-12|Pacific Biosciences Of California, Inc.|Reactive surfaces, substrates and methods for producing and using same|

US7763423B2|2005-09-30|2010-07-27|Pacific Biosciences Of California, Inc.|Substrates having low density reactive groups for monitoring enzyme activity|

US20080267878A1|2005-10-04|2008-10-30|Koninklijke Philips Electronics, N.V.|Targeted Imaging And/Or Therapy Using The [3+2] Azide-Alkyne Cycloaddition|

JP2009511053A|2005-10-12|2009-03-19|ザスクリップスリサーチインスティテュート|Selective post-translational modification of phage-displayed polypeptides|

US20100247433A1|2005-10-14|2010-09-30|California Institute Of Technology|Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells|

WO2007047796A2|2005-10-17|2007-04-26|Institute For Systems Biology|Tissue-and serum-derived glycoproteins and methods of their use|

CN101534865A|2005-10-19|2009-09-16|Ibc药品公司|Methods and compositions for generating bioactive assemblies of increased complexity and uses|

US20070178133A1|2005-11-09|2007-08-02|Liquidia Technologies, Inc.|Medical device, materials, and methods|

WO2008048288A2|2005-11-09|2008-04-24|Montana State University|Novel nanoparticles and use thereof|

US20070254006A1|2006-02-15|2007-11-01|Massachusetts Institute Of Technology|Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides|

US20070122443A1|2005-11-29|2007-05-31|Narayanan Pallassana V|Amphiphilic copolymer compositions|

US20070122550A1|2005-11-30|2007-05-31|Narayanan Pallassana V|Amphiphilic polymeric coating|

US8944804B2|2006-01-04|2015-02-03|Liquidia Technologies, Inc.|Nanostructured surfaces for biomedical/biomaterial applications and processes thereof|

US20090038701A1|2006-01-17|2009-02-12|Baxter International Inc.|Device, system and method for mixing|

US8716033B2|2006-02-10|2014-05-06|Life Technologies Corporation|Oligosaccharide modification and labeling of proteins|

US8114636B2|2006-02-10|2012-02-14|Life Technologies Corporation|Labeling and detection of nucleic acids|

US8222423B2|2006-02-14|2012-07-17|Dana-Farber Cancer Institute, Inc.|Bifunctional histone deacetylase inhibitors|

WO2007104948A2|2006-03-10|2007-09-20|Warwick Effect Polymers Ltd.|Polymers|

US7909928B2|2006-03-24|2011-03-22|The Regents Of The University Of Michigan|Reactive coatings for regioselective surface modification|

US8206779B2|2006-03-24|2012-06-26|Fujifilm Corporation|Method for producing laminate, polarizing plate, and image display device|

US20070237803A1|2006-04-11|2007-10-11|Medtronic Vascular, Inc.|Biodegradable Biocompatible Amphiphilic Copolymers for Coating and Manufacturing Medical Devices|

CA2861601A1|2006-04-27|2007-11-08|Intezyne Technologies, Inc.|Poly containing chemically disparate endgroups|

US20090253609A1|2006-05-15|2009-10-08|Rhodia Operations|Hybrid compounds based on silicones, and at least one other molecular entity, polymer or otherwise, especially of the polyol type, method for the preparation thereof, and applications of the same|

US8501478B2|2006-06-15|2013-08-06|University Of Cincinnati|Trehalose click polymers for delivery of biologically active molecules|

WO2008013618A1|2006-06-21|2008-01-31|Dendritic Nanotechnologies, Inc.|Process for preparing alkyne intermediates for dendritic polymers|

US20100159508A1|2006-07-06|2010-06-24|Agency For Science, Technology And Research|Thermally responsive micelles|

WO2008006097A2|2006-07-07|2008-01-10|Intezyne Technologies Llc|Covalent modification of metal surfaces|

US20090053139A1|2006-07-12|2009-02-26|Regents Of The University Of Michigan|Dendrimer based compositions and methods of using the same|

US20100021391A1|2006-07-14|2010-01-28|Montana State University|Novel nanoparticles for biofilm targeting|

US20080015138A1|2006-07-17|2008-01-17|Affinergy, Inc.|Metal binding compounds, metal binding compositions, and their uses|

WO2008011351A2|2006-07-19|2008-01-24|Boston Scientific Scimed, Inc.|Apparatus for tissue resection|

WO2008016371A1|2006-08-01|2008-02-07|The Trustees Of Columbia University In The City Ofnew York|Macromonomers for preparation of degradable polymers and model networks|

EP2046391A4|2006-08-02|2013-03-20|Univ Nebraska|Drug carriers, their synthesis, and methods of use thereof|

JP5567337B2|2006-08-18|2014-08-06|コモンウェルスサイエンティフィックアンドインダストリアルリサーチオーガナイゼーション|Polymer coatings and methods for forming them|

WO2008024435A2|2006-08-23|2008-02-28|Vanderbilt University|Dendritic molecular intracellular transporters and methods of making and using same|

US7985783B2|2006-09-21|2011-07-26|The Regents Of The University Of California|Aldehyde tags, uses thereof in site-specific protein modification|

CN101652405A|2006-10-17|2010-02-17|国家淀粉及化学投资控股公司|1 of trinitride and alkynes, the cycloaddition of 3-dipole|

FR2907456B1|2006-10-20|2009-01-16|Biocydex Soc Par Actions Simpl|PROCESS FOR THE PREPARATION OF OLIGOMERS OR POLYMERS OF CYCLODESTRINS|

US7861893B2|2006-11-10|2011-01-04|Ethicon Endo-Surgery, Inc.|Adhesive dispenser for surgery|

US20100069578A1|2006-11-17|2010-03-18|Rudolf Faust|Functional Hydrocarbon Polymers and Process for Producing Same|

WO2008075955A2|2006-12-21|2008-06-26|Stichting Voor De Technische Wetenschappen|Process for the preparation of 1,4,5-trisubstituted triazoles and 3,4,5-trisubstituted triazoles|

WO2008077406A2|2006-12-22|2008-07-03|Aalborg Universitet|Coupling of elements|

WO2008081044A1|2007-01-05|2008-07-10|Technische Universität München|Apparatus and method for the detection of forces in the sub-micronewton range|

US20080171067A1|2007-01-17|2008-07-17|Immunomedics, Inc.|Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites|

EP2125855A4|2007-01-26|2013-03-27|Hope City|Methods and compositions for the treatment of cancer or other diseases|

US20080199736A1|2007-02-16|2008-08-21|Gadeken Larry L|Apparatus for generating electrical current from radioactive material and method of making same|

US7622532B2|2007-02-16|2009-11-24|William Marsh Rice University|Synthesis of radioactive materials and compositions of same|

WO2008106657A2|2007-03-01|2008-09-04|Intezyne Technologies, Inc.|Encapsulated amyloid-beta peptides|

WO2008109483A1|2007-03-02|2008-09-12|The Board Of Trustees Of The University Of Illinois|Particulate drug delivery|

WO2008108736A1|2007-03-06|2008-09-12|Agency For Science, Technology And Research|Particles for delivery of bioactive factors|

WO2008115694A2|2007-03-16|2008-09-25|Medtronic, Inc.|Polymerization of multifunctional azides, and polymers therefrom|

US7910319B2|2007-03-23|2011-03-22|Academia Sinica|Glycoproteomic probes for fluorescent imaging fucosylated glycans in vivo|

US8277711B2|2007-03-29|2012-10-02|E I Du Pont De Nemours And Company|Production of nanofibers by melt spinning|

WO2008121375A2|2007-03-29|2008-10-09|Pacific Biosciences Of California, Inc.|Modified surfaces for immobilization of active molecules|

EP1975230A1|2007-03-30|2008-10-01|Capsulution Nanoscience AG|Method for forming glucose sensing micro-particles, use of micro-particles, and kit|

AT530169T|2007-09-28|2011-11-15|Bind Biosciences Inc|CANCER TARGETING WITH NANOPARTICLES|

GB0706243D0|2007-03-30|2007-05-09|Univ Southampton|Modified nucleic acids|

US7798385B2|2007-05-16|2010-09-21|The Invention Science Fund I, Llc|Surgical stapling instrument with chemical sealant|

US7909795B2|2007-07-05|2011-03-22|Baxter International Inc.|Dialysis system having disposable cassette and interface therefore|

US20090018646A1|2007-07-10|2009-01-15|Zhao Jonathon Z|Coating Employing an Anti-Thrombotic Conjugate|

EP2090592A1|2007-07-31|2009-08-19|OctoPlus Sciences B.V.|Biodegradable hydrogels based on click chemistry|

US8394914B2|2007-08-24|2013-03-12|Board Of Trustees Of Michigan State University|Functional polyglycolide nanoparticles derived from unimolecular micelles|

US8927682B2|2007-08-24|2015-01-06|Board Of Trustees Of Michigan State University|Functionalization of polyglycolides by “click” chemistry|

CN101827564A|2007-09-04|2010-09-08|阿费内基有限公司|Methods and compositions for delivery of growth factor to fibrous connective tissue|

EP2209496B1|2007-11-05|2019-05-08|Vanderbilt University|Multifunctional degradable nanoparticles with control over size and functionalities|

JP2011503188A|2007-11-14|2011-01-27|ザリージェンツオブザユニバーシティオブカリフォルニア|Sterol-modified amphiphilic lipids|

US8092855B2|2007-11-28|2012-01-10|California Institute Of Technology|Click chemistry surface functionalization for resonant micro-cavity sensors|

EP3574909A1|2008-01-30|2019-12-04|Imbed Biosciences, Inc.|Methods and compositions for wound healing|

US8034396B2|2008-04-01|2011-10-11|Tyco Healthcare Group Lp|Bioadhesive composition formed using click chemistry|

WO2009129630A1|2008-04-25|2009-10-29|Interface Biologics Inc.|Covalently grafted pharmaceutically active polymers|

WO2009136853A1|2008-05-07|2009-11-12|Polymer Factory Sweden Ab|Dendrimers with interior and exterior functionalities comprising of azide or alkyne groups for post- functionalization by huisgen click cycloaddition|

MX2010012236A|2008-05-13|2011-06-20|Univ Washington|Polymeric carrier.|

DK2396036T3|2009-02-13|2017-10-16|Immunomedics Inc|Immune conjugates with an intracellular cleavable compound|

WO2010095049A1|2009-02-21|2010-08-26|Sofradim Production|Crosslinked fibers and method of making same by extrusion|

EP2398524B1|2009-02-21|2017-07-12|Covidien LP|Medical devices having activated surfaces|

CA2753173C|2009-02-21|2017-05-30|Sofradim Production|Medical devices with an activated coating|CA2753173C|2009-02-21|2017-05-30|Sofradim Production|Medical devices with an activated coating|

EP2398524B1|2009-02-21|2017-07-12|Covidien LP|Medical devices having activated surfaces|

CZ2009836A3|2009-12-11|2011-06-22|Contipro C A.S.|Hyaluronic acid derivative oxidized in position 6 of saccharide glucosamine portion selectively to aldehyde, process of its preparation and modification method thereof|

CZ2009835A3|2009-12-11|2011-06-22|Contipro C A.S.|Process for preparing hyaluronic acid derivative oxidized in position 6 of saccharide glucosamine portion selectively to aldehyde and modification method thereof|

WO2012001532A2|2010-07-01|2012-01-05|Sofradim Production|Medical device with predefined activated cellular integration|

CZ303879B6|2012-02-28|2013-06-05|Contipro Biotech S.R.O.|Derivatives based on hyaluronic acid capable of forming hydrogels, process of their preparation, hydrogels based on these derivatives, process of their preparation and use|

CZ304512B6|2012-08-08|2014-06-11|Contipro Biotech S.R.O.|Hyaluronic acid derivative, process for its preparation, modification process and use thereof|

CZ2012842A3|2012-11-27|2014-08-20|Contipro Biotech S.R.O.|C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof|

CZ2012843A3|2012-11-27|2014-02-05|Contipro Biotech S.R.O.|Endless fibers based on hyaluronate selectively oxidized in position 6 N-acetyl-D-glucosamine portion, their preparation, use, threads, yatns, fabrics and process for preparing thereof|

CZ305153B6|2014-03-11|2015-05-20|Contipro Biotech S.R.O.|Conjugates of hyaluronic acid oligomer or a salt thereof, process for their preparation and use|

CZ2014451A3|2014-06-30|2016-01-13|Contipro Pharma A.S.|Antitumor composition based on hyaluronic acid and inorganic nanoparticles, process of its preparation and use|

CZ2015166A3|2015-03-09|2016-09-21|Contipro Biotech S.R.O.|Delf-supporting, biologically degradable film based on hydrophobized hyaluronic acid, process of its preparation and use|

CZ306479B6|2015-06-15|2017-02-08|Contipro A.S.|A method of crosslinking polysaccharides by using photolabile protecting groups|

CZ306662B6|2015-06-26|2017-04-26|Contipro A.S.|Sulphated polysaccharides derivatives, the method of their preparation, the method of their modification and the use|

JP2017140110A|2016-02-08|2017-08-17|テルモ株式会社|Treatment method and medical device|

CZ308106B6|2016-06-27|2020-01-08|Contipro A.S.|Unsaturated derivatives of polysaccharides, preparing and using them|

法律状态:
2015-11-12| FGA| Letters patent sealed or granted (standard patent)|

优先权:

申请号 | 申请日 | 专利标题

US15438309P| true| 2009-02-21|2009-02-21||

US61/154,383||2009-02-21||

PCT/IB2010/000665|WO2010095056A2|2009-02-21|2010-02-22|Medical devices with an activated coating|

[返回顶部]